glp 1 chronic kidney disease Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Disease: A Narrative Review of the Key Evidence with Practical Considerations | Diabetes Therapy SGLT2 vs GLP-1 for CKD:

This early GLP-1-mediated enhancement of insulin sensitivity represents a novel physiological function of GLP-1

The study utilized a single-blind, randomized, placebo-controlled, crossover design, combined with functional magnetic resonance imaging (fMRI), to analyze the performance of 54 participants (30 with normal insulin sensitivity and 24 with impaired insulin sensitivity) on sensory associative learning tasks while receiving liraglutide and placebo treatments.435 Liraglutide significantly enhanced associative learning abilities in obese individuals with impaired insulin sensitivity

Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS et al (2021) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

He et al

For complete documentation checklists and PA preparation: Wegovy Prior Authorization Guide YOUR PLAN COVERS IT If Your PA Was Denied If Your PA Was Denied Your plan covers Wegovy, but the prior authorization was rejected